Plasma Cell Disorders Diagnosis and Monitoring

Initial Evaluation

• The International Myeloma Society and the National Comprehensive Cancer Network recommend a comprehensive panel for initial evaluation of patients with suspected plasma cell disorders, including serum protein electrophoresis (SPEP) with quantification of protein fractions, serum immunofixation electrophoresis (SIFE), serum free light chain (FLC) assay, 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE), as well as complete blood count with differential, serum chemistry panel, quantitative immunoglobulins, serum beta-2 microglobulin, and lactate dehydrogenase 1, 2, 3, 4
• The initial testing panel should include SPEP, SIFE, serum FLC assay, quantitative immunoglobulins, and 24-hour urine for UPEP and UIFE, with a strength of evidence supported by the National Comprehensive Cancer Network 3, 4

Diagnostic Criteria

• The presence of monoclonal protein can be detected with higher sensitivity when SPEP and serum free light chain assay are used together than SPEP alone, and a 24-hour urine collection for UPEP and UIFE should be performed simultaneously, as recommended by the International Myeloma Society and the National Comprehensive Cancer Network 1, 3
• If monoclonal protein is detected, quantify the M-protein, identify type through immunofixation, and proceed with bone marrow examination and imaging studies, with a strength of evidence supported by the National Comprehensive Cancer Network 1, 3, 4

• The diagnostic approach should follow an algorithm that includes:

  Step	Test
  1	Assessing the overall pattern
  2	Quantifying M-protein
  3	Ordering serum immunofixation electrophoresis (SIFE) to identify type
  4	Ordering serum free light chain (FLC) assay
  5	Ordering 24-hour urine for protein electrophoresis (UPEP) and immunofixation (UIFE) if a monoclonal spike is detected

  3

Monitoring and Follow-up

• For low-risk monoclonal gammopathy of undetermined significance (MGUS), repeat SPEP in 6 months, and if stable, every 2-3 years thereafter, as recommended by the International Myeloma Society and the National Comprehensive Cancer Network 5, 3, 4
• For intermediate/high-risk MGUS, baseline bone marrow examination, follow-up with SPEP and CBC in 6 months, and then annually for life, with a strength of evidence supported by the National Comprehensive Cancer Network 5, 3, 4
• For solitary plasmacytoma, smoldering myeloma, and MGUS, follow-up should be performed every 3-6 months, with risk stratification guiding the frequency of follow-up for MGUS, as recommended by the National Comprehensive Cancer Network 3, 4
• The frequency of SPEP testing varies depending on the condition:

Specimen Collection and Testing

• A 24-hour urine collection is required for accurate quantification of urinary protein excretion, and a random urine sample is insufficient, as recommended by the International Myeloma Society and the National Comprehensive Cancer Network 1, 3
• Serum protein electrophoresis (SPEP) separates serum proteins into five main fractions, including albumin, alpha-1, alpha-2, beta, and gamma, and identifies abnormal patterns in protein distribution, including monoclonal proteins that may indicate multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, solitary plasmacytoma, or amyloidosis, with a strength of evidence supported by the National Comprehensive Cancer Network 7, 3
• Quantitative immunoglobulin levels (IgG, IgA, IgM) provide information about specific antibody types and are essential for detecting abnormalities in protein metabolism, according to the National Comprehensive Cancer Network 8, 3, 6
• Serum free light chain (FLC) assay is essential for detecting light chain disease, especially when SPEP is negative but clinical suspicion remains high, with a strength of evidence supported by the National Comprehensive Cancer Network 7, 3, 9
• Common pitfalls in SPEP interpretation include:
• Serum protein electrophoresis (SPEP) specimens should be collected in a serum-separator tube or red-top tube with a minimum volume of 0.5 mL, though 3 mL is recommended for testing, as recommended by the National Comprehensive Cancer Network 10
• The specimen should be centrifuged with only serum sent for analysis, which can be stored refrigerated for up to 1 week or frozen indefinitely, according to the National Comprehensive Cancer Network 10
• The specimen label must include the patient's identifier and collection date, and overnight delivery via cold pack or frozen preferred, or room temperature (20-25°C) is acceptable, as recommended by the National Comprehensive Cancer Network 10